Frequent chronic obstructive pulmonary disease exacerbators: How much real, how much fictitious

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 7, Issue 4, 2010, Pages 276-284

  Soler Catalua, Juan José ^a   Rodriguez Roisin, Roberto ^b  

^a HOSPITAL GENERAL DE REQUENA   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Daily life activities; Definition; Frequency; Lung function; Mortality; Quality of life

Indexed keywords

MANNOSE BINDING LECTIN 2;

BACTERIAL INFECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DISEASE PREDISPOSITION; FREQUENCY ANALYSIS; HOST RESISTANCE; HUMAN; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; RECURRENT DISEASE; REVIEW; TREATMENT FAILURE; VIRUS INFECTION;

DISEASE PROGRESSION; FORCED EXPIRATORY VOLUME; HUMANS; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE;

EID: 77955178625     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2010.496817     Document Type: Review

References (61)

1. Andersson F, Borg S, Jansson SA, Jonsson AC, Ericsson A, Prutz C, Ronmark E, Lundback B. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med 2002; 96:700-708.
2. Seemungal TAR, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157:1418-1422.
3. Miravitlles M, Ferrer M, Pont A, Zalacain R, Alvarez-Sala JL, Masa F, Verea H, Murio C, Ros F, Vidal R; IMPAC Study Group. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 years follow-up study. Thorax 2004; 59:387-395.
4. Soler JJ, Sánchez L, Román P, Martinez MA, Perpiña M. Risk factors of emergency care and admissions in COPD patients with high consumption of health resources. Respir Med 2004; 98:318-329.
5. Spencer S, Calverley PMA, Burge PS, Jones PW. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004; 23:698-702.
6. Bourbeau J, Ford G, Zackon H, Pinsky N, Lee J, Ruberto G. Impact on patients' health status following early identification of a COPD exacerbation. Eur Respir J 2007; 30:907-913.
7. Kanner RE, Anthonisen NR, Connett JE. Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex- smokers with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164:358-364.
8. Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57:847-852.
9. Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60:925-931.
10. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J 2003; 21(41):46s-53s.
11. Miravitlles M, Guerrero T, Mayordomo C, Sánchez-Agudo L, Nicolau F, Segu JL and on behalf of the EOLO group. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. Respiration 2000; 67:495-501.
12. Soler JJ, Sánchez L, Latorre M, Alamar J, Román P, Perpiña M. The impact of COPD on hospital resources: the specific burden of COPD patients with high rates of hospitalization. Arch Bronconeumol 2001; 37:375-381.
13. Lomas DA, Silverman EK, Edwards LD, Locantore NW, Miller BE, Horstman DH, Tal-Singer R. Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. Eur Respir J 2009; 34:95-102.
14. Sullivan SD, Ramsey SC, Todd AL, Pharm D. The economic burden in COPD. Chest 2000; 117:5S-9S.
15. Cote CG, Dordelly LJ, Celli BR. Impact of COPD exacerbations on patient-centered outcomes. Chest 2007; 131:696-704.
16. Makris D, Moschandreas J, Damianaki A, Ntaoukakis E, Siafakas NM, Milic Emili J, Tzanakis N. Exacerbations and lung function decline in COPD: new insights in current and ex-smokers. Respir Med 2007; 101:1305-1312.
17. Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PM. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008; 178:332-338.
18. Connors AF, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. Am J Respir Crit Care Med 1996; 154:959-967.
19. Almagro P, Calbo E, Ochoa de Echagiien A, Barreiro B, Quin- tana S, Heredia JL, Garau J. Mortality after hospitalization for COPD. Chest 2002; 121:1441-1448.
20. Groenewegen KH, Schols AMWJ, Wouters E. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 2003; 124:459-467.
21. Soler-Cataluña JJ, Martrnez-Garcfa MA, Sánchez L, Perpiña M, Román P. Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients. Respir Med 2009; 103:692-699.
22. Kessler R, Stähl E, Vogelmeir C, Haughmey J, Trudeau E, Lofdahl C-G, Partridge MR. Patient understanding, detection, and experience of COPD exacerbations: an observational, interview- based study. Chest 2006; 130:133-142.
23. Donaldson GC, Wilkinson TMA, Hurst JR, Perera WR, Wedzicha JA. Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 171:446-452.
24. Quint JK, Baghai-Ravary R, Donaldson GZ, Wedzicha JA. Relationship between depression and exacerbations in COPD. Eur Respir J 2008; 32:53-60.
25. Tashkin D, Decramer M, Mannino D, Leimer I, Kesten S. Elevated incidence of serious non-respiratory adverse event following COPD exacerbations in clinical trials. Am J Respir Crit Care 2008; 177:A132.
26. Decramer M, Gosselink R, Troosters T, Verschueren M, Evers G. Muscle weakness is related to utilization of health care resources in COPD patients. Eur Respir J 1997; 10:417-423.
27. Hurst JR, Donaldson GC, Quint JK, Goldring JJP, Baghai Ravary R, Wedzicha J. Temporal clustering of exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 179: 369-374.
28. Langsetmo L, Platt RW, Ernst P, Bourbeau J. Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. Am J Respir Crit Care Med 2008; 177:396-401. (Pubitemid 351317582)
29. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359:1543-1554.
30. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789.
31. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987; 106:196-204.
32. Miravitlles M. Exacerbations of chronic obstructive pulmonary disease: when are bacteria important? Eur Respir J 2002; 20(36):9s-19s. (Pubitemid 34774184)
33. Miravitlles M, Murio C, Guerrero T, Gisbert R. Costs of chronic bronchitis and COPD: a one-year follow-up study. Chest 2003; 123:784-791.
34. Donaldson GC, Wedzicha JA. COPD exacerbations. 1: Epidemiology. Thorax 2006; 61:164-168.
35. Perera WR, Hurst JR, Wilkinson TMA, Sapsford RJ, Müllerova H, Donaldson GC, Wedzicha JA. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J 2007; 29:527-534.
36. Kessler R, Stähl E, Vogelmeir C, Haughmey J, Trudeau E, Lofdahl C-G, Partridge MR. Patient understanding, detection, and experience of COPD exacerbations: an observational, interview- based study. Chest 2006; 130:133-142.
37. Seemungal TAR, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patient with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161:1608-1613.
38. Spencer S, Jones PW; GLOBE Study Group. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 2003; 58:589-593.
39. Aaron SD, Fergusson D, Marks GB, Suissa S, Vandemheen KL, Doucette S, Maltais F, Bourbeau JF, Goldstein RS, Bal- ter M, O'Donnell D, Fitzgerald M; Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Counting, analysing and reporting exacerbations of COPD in randomised controlled trials. Thorax 2008; 63:122-128.
40. Aaron SD, Vandemheen KL, Fergusson D,Maltais F, Bourbeau J, Goldstein R, Balter M, ODonnell D, McIvor A, Sharma S, Bishop G, Anthony J, Cowie R, Field S, Hirsch A, Hernandez P, Rivington R, Road J, Hoffstein V, Hodder R, Marciniuk D, McCormack D, Fox G, Cox G, Prins HB, Ford G, Bleskie D, Doucette S, Mayers I, Chapman K, Zamel N, FitzGerald M; Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease. Ann Intern Med 2007; 146:545-555.
41. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingwoth K, Efthimiou J. Multicentre randomised in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 20:1297-1303.
42. Dewan NA, Rafique S, Kanwar B, Satpathy H, Ryschon K, Tillotson GS, Niederman MS. Acute exacerbation of COPD: factors associated with poor outcome. Chest 2000; 117:662-671.
43. García-Aymerich J, Farrero E, Felez MA, Izquierdo J, Marrades RM, Anto JM. Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. Thorax 2003; 58:100-105.
44. Niewoehner DE, Lokhnygina Y, Rice K, Kuschner WG, Sharafkhaneh A, Sarosi GA, Krumpe P, Pieper K, Kesten S. Risk indexes for exacerbations and hospitalizations due to COPD. Chest 2007; 131:20-28.
45. Bhowmik A, Seemungal TAR, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000; 55:114-120.
46. Patel IS, Seemungal TAR, Wiks M, Lloyd-Owen SJ, Donaldson GC, Wedzicha JA. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 2002; 57:759-764.
47. Sethi S, Sethi R, Eschberger K, Lobbins P, Cai X, Grant BJ, Murphy TF. Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 176:356-361.
48. Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, Caramori G, Fabbri LM, Johnston SL. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006; 173:1114-1121. (Pubitemid 43726892)
49. Hurst JR, Donaldson GC, Wilkinson TMA, Perera WR, Wedzicha JA. Epidemiological relationships between the common cold and exacerbation frequency in COPD. Eur Respir J 2005; 26:846-852.
50. Donaldson GC, Seemungal TAR, Patel IS, Lloyd-Owen SS, Bhowmik A, Wilkinson TMA, Maccallum PK, Wedzicha JA. Airway and systemic inflammation and decline in lung function, in chronic obstructive pulmonary disease. Chest 2005; 128:1995-2004.
51. Burgel PR, Nesme-Meyer P, Chanez P, Caillaud D, Carré P, Perez T, Roche N. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest 2009; 135:975-982.
52. Sala E, Villena C, Fernández-Palomeque C, Ríos A, Martiinez H, Garcia-Cosio B. Increased levels of circulating endothelial progenitor cells during exacerbations in COPD. Eur Respir J 2007; 30(51):39s.
53. Abroug F, Quanes-Besbes L, Nciri N, Sellami N, Addad F, Ben Hamda K, Amor AB, Najjar MF, Knani J. Association of left-heart dysfunction with severe exacerbation of chronic obstructive pulmonary disease. diagnostic performance of cardiac biomarkers. Am J Respir Crit Care Med 2006; 174:990-996.
54. Harvey MG, Hancox RJ. Elevation of cardiac troponins in exacerbation of chronic obstructive pulmonary disease. Emerg Med Australas 2004; 16:212-215.
55. Wedzicha JA, Seemungal TA, MacCallum PK, Paul EA, Donaldson GC, BhowmikA, Jeffries DJ. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost 2000; 84:210-215.
56. Tille-Leblond I, Marquette CH, Perez T, Scherpereel A, Zanetti C, Tonnel AB, Remy-Jardin M. Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors. Ann Intern Med 2006; 144:390-396.
57. Rutschmann OT, Cornuz J, Poletti PA, Bridevaux PO, Hugli OW, Qanadli SD, Perrier A. Should pulmonary embolism be suspected in exacerbations of chronic obstructive pulmonary disease? Thorax 2007; 62:121-125.
58. Takabatake N, Shibata Y, Abe S, Wada T, Machiya JI, Igarashi A, Ji G, Sato H, Sata M, Takeishi Y, Emi M, Muramatsu M, Kub- ota I. A single nucleotide polymorphism in the CCL1 gene predicts acute exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174:875-885.
59. Yang IA, Seeney SL, Wolter JM, Anders EM, McCormack JG, Tunnicliffe AM, Rabnott GC, Shaw JG, Dent AG, Kim ST, Zimmerman PV, Fong KM. Mannose-binding lectin gene polymorphism predicts hospital admissions for COPD infections. Genes and Immunity 2003; 4:269-274.
60. Foreman MG, DeMeo DL, Hersh CP, Carey VJ, Fan VS, Reilly JJ, Shapiro SD, Silverman EK. Polymorphic variation in surfactant protein B is associated with COPD exacerbations. Eur Respir J 2008; 32:938-944.
61. van Iwaarden JF, Claassen E, Jeurissen SH, Haagsman HP, Kraal G. Alveolar macrophages, surfactant lipids, and surfactant protein B regulate the induction of immune responses via the airways. Am J Respir Cell Mol Biol 2001; 24:452-458.